The executive summary of the American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions coronary artery revascularization guideline provides ...the top 10 items readers should know about the guideline. In the full guideline, the recommendations replace the 2011 coronary artery bypass graft surgery guideline and the 2011 and 2015 percutaneous coronary intervention guidelines. This summary offers a patient-centric approach to guide clinicians in the treatment of patients with significant coronary artery disease undergoing coronary revascularization, as well as the supporting documentation to encourage their use.
A comprehensive literature search was conducted from May 2019 to September 2019, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Collaboration, CINHL Complete, and other relevant databases. Additional relevant studies, published through May 2021, were also considered. Structure: Recommendations from the earlier percutaneous coronary intervention and coronary artery bypass graft surgery guidelines have been updated with new evidence to guide clinicians in caring for patients undergoing coronary revascularization. This summary includes recommendations, tables, and figures from the full guideline that relate to the top 10 take-home messages. The reader is referred to the full guideline for graphical flow charts, supportive text, and tables with additional details about the rationale for and implementation of each recommendation, and the evidence tables detailing the data considered in the development of this guideline.
Clopidogrel, prasugrel, and ticagrelor are antiplatelet drugs that act by inhibiting the platelet P2Y
12
receptor. Any one of them is usually combined with low-dose aspirin as dual antiplatelet ...therapy in patients who have acute coronary syndromes or who are undergoing coronary stent implantation to decrease the risk of subsequent platelet-mediated thrombotic cardiovascular events. Many investigations have been performed to determine whether these clinical indications should be broadened. The PARTHENON clinical development program
1
for ticagrelor included five randomized, controlled, double-blind trials across the spectrum of cardiovascular diseases (Table 1). In patients who were admitted to the hospital for myocardial infarction or . . .
PDF
